Suppr超能文献

近期对抗 COVID-19 及相关冠状病毒的潜在药物疗法的进展——一种观点。

Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-A perspective.

机构信息

Laboratory of Medicinal Plant Biotechnology, College of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.

Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul, 05029, South Korea.

出版信息

Food Chem Toxicol. 2021 Aug;154:112333. doi: 10.1016/j.fct.2021.112333. Epub 2021 Jun 10.

Abstract

Coronaviruses (CoVs) are a large family of viruses responsible for the severe pathophysiological effects on human health. The most severe outbreak includes Severe Acute Respiratory Syndrome (SARS-CoV), Middle East Respiratory Syndrome (MERS-CoV) and Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 poses major challenges to clinical management because no specific FDA-approved therapy yet to be available. Thus, the existing therapies are being used for the treatment of COVID-19, which are under clinical trials and compassionate use, based on in vitro and in silico studies. In this review, we summarize the potential therapies utilizing small molecules, bioactive compounds, nucleoside and nucleotide analogs, peptides, antibodies, natural products, and synthetic compounds targeting the complex molecular signaling network involved in COVID-19. In this review>230 natural and chemically synthesized drug therapies are described with their recent advances in research and development being done in terms of their chemical, structural and functional properties. This review focuses on possible targets for viral cells, viral proteins, viral replication, and different molecular pathways for the discovery of novel viral- and host-based therapeutic targets against SARS-CoV-2.

摘要

冠状病毒(CoV)是一大类病毒,可对人类健康造成严重的病理生理影响。最严重的爆发包括严重急性呼吸综合征(SARS-CoV)、中东呼吸综合征(MERS-CoV)和由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)。COVID-19 对临床管理构成重大挑战,因为尚未有获得美国食品和药物管理局(FDA)批准的特定疗法。因此,正在根据体外和计算机模拟研究,使用临床试验和同情用药来治疗 COVID-19,而正在使用的现有疗法包括小分子、生物活性化合物、核苷和核苷酸类似物、肽、抗体、天然产物和针对 COVID-19 涉及的复杂分子信号网络的合成化合物。在这篇综述中,我们总结了利用小分子、生物活性化合物、核苷和核苷酸类似物、肽、抗体、天然产物和针对 COVID-19 涉及的复杂分子信号网络的合成化合物等方法的潜在疗法。在这篇综述中,描述了超过 230 种天然和化学合成的药物疗法,并根据其化学、结构和功能特性,介绍了它们在研究和开发方面的最新进展。本综述重点介绍了针对病毒细胞、病毒蛋白、病毒复制以及不同分子途径的可能靶点,以发现针对 SARS-CoV-2 的新型病毒和基于宿主的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c9c/8189744/84440eea55a5/ga1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验